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E-mail address: t.teerlink@vumc.nl (T. Teerlink).Low plasma homoarginine has emerged as a risk marker for cardiovascular disease. We exploited
cells of a patient with a rare inborn error of metabolism to explore potential pathways of homoar-
ginine synthesis, using stable isotopes and mass spectrometry. Control lymphoblasts, as opposed to
lymphoblasts from an arginine:glycine amidinotransferase (AGAT)-deﬁcient patient, were able to
synthesize homoarginine from arginine and lysine. In contrast, in a patient with a deﬁciency of
the urea cycle enzyme argininosuccinate synthase, plasma homoarginine was not decreased. We
conclude that promiscuous activity of AGAT, a key enzyme in creatine synthesis, plays a pivotal role
in homoarginine synthesis.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Homoarginine, a homolog of arginine, is often measured simul-
taneously with arginine and asymmetric dimethylarginine
(ADMA), one of the methylated forms of arginine [1,2]. ADMA is
an endogenous inhibitor of the production of nitric oxide from
arginine by nitric oxide synthase (NOS) [3,4] and elevated ADMA
is associated with cardiovascular disease [5,6]. Homoarginine dif-
fers from arginine by the presence of an additional methylene
group in the carbon chain. Because of this structural similarity,
homoarginine may act as a competing substrate or inhibitor of en-
zymes that use arginine as substrate. Homoarginine has indeed
been shown to act as substrate for NOS [7,8], and may thus in-
crease nitric oxide production. However, compared to arginine,
the Km value of homoarginine is much higher, reﬂecting a lower
catalytic efﬁciency of NOS using homoarginine as substrate [7,8].
In addition, homoarginine, by competing with arginine for cellular
uptake, may limit the amount of intracellular arginine [9]. There-
fore, despite homoarginine being a substrate for NOS, production
of nitric oxide may be reduced at a high homoarginine to arginine
ratio. Taken together, homoarginine may affect the cardiovascular
system by either enhancing or limiting nitric oxide production. Inchemical Societies. Published by E
al Chemistry, VU University
, 1007 MB Amsterdam, Theaddition, homoarginine, being an inhibitor of liver and bone alka-
line phosphatase [10], may also be relevant to bone metabolism.
Lowserumhomoargininehas recently emergedas a potential new
riskmarker for stroke [11] and cardiovascularmortality [12–14], and
in a study among female nursing home patients, low serum homoar-
ginine was associated with high bone turnover [15]. To increase our
understanding of the role of homoarginine in cardiovascular and
other diseases, it is important to unravel the metabolic pathways in-
volved in homoarginine synthesis and degradation in humans.
Evidence for in vivo synthesis of homoarginine from lysine was
ﬁrst reported in rats, where 14C-labeled homoarginine was mea-
sured in liver and kidney after injection of 14C-labeled lysine [16].
In humans, an increase in urinary homoarginine after oral lysine
administration has been demonstrated in adults [16] aswell as chil-
dren [17]. The metabolic routes responsible for homoarginine syn-
thesis from lysine in vivo have not yet been unraveled completely.
Fig. 1 shows a schematic representation of the two pathways that
have been suggested in literaturemost often. The ﬁrst pathway uses
arginine:glycine amidinotransferase (AGAT; EC 2.1.4.1.). The
primary role of AGAT is the production of guanidino acetic acid
(GAA) from arginine and glycine in the ﬁrst step of the creatine-syn-
thesis pathway [18]. This makes AGAT an important enzyme in
maintenance of energy metabolism in different tissues, including
the myocardium [19]. When AGAT uses lysine instead of glycine
as amidino-acceptor, homoarginine is formed instead of GAA
[20,21]. The second pathway for homoarginine synthesis that has
been suggested in literature uses the urea-cycle enzymes
[22,23], in which instead of ornithine, lysine is used by ornithinelsevier B.V. All rights reserved.
Fig. 1. Suggested metabolic routes for homoarginine formation and degradation.
The main function of arginine:glycine amidinotransferase (AGAT) is the transfer of
an amidino-group from arginine to glycine, resulting in formation of guanidino
acetic acid, which is subsequently methylated by guanidinoacetate methyltrans-
ferase (GAMT) to form creatine. However, when AGAT uses lysine instead of glycine
as acceptor of the amidino-group, homoarginine is formed. Another possible
pathway for homoarginine synthesis is by the enzymes of the urea cycle. When
lysine instead of ornithine is used as substrate by ornithine transcarbamoylase
(OTC), homocitrulline is formed, which can be converted into homoargininosucci-
nate by argininosuccinate synthase (ASS) and subsequently into homoarginine by
argininosuccinate lyase (ASL). Because of its structural similarity to arginine,
homoarginine can be used as substrate by arginase, forming lysine and urea, or by
nitric oxide synthase (NOS) forming nitric oxide (NO) and homocitrulline.
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instead of citrulline. Next, homocitrulline is converted into homoar-
gininosuccinate by argininosuccinate synthase (ASS; EC 6.3.4.5.),
and subsequently into homoarginine by argininosuccinate lyase
(ASL; EC 4.3.2.1.).
In the present studywehave exploited rare inborn errors ofmetab-
olism to gainmore insight in the de novo synthesis of homoarginine in
humans, using stable isotopes andmass spectrometry. To this end, the
capacity for homoarginine synthesis in lymphoblasts from a patient
affectedwithAGAT-deﬁciencywas compared to control lymphoblasts.
Furthermore, the concentration of homoarginine in plasma of an
ASS-deﬁcient patientwas compared to levels in age-matched controls.
2. Materials and methods
2.1. Chemicals and reagents
RPMI-medium, Earls balanced salt solution (EBSS), and Hanks
balanced salt solution (HBSS) were obtained from Invitrogen,
(Carlsbad, CA, USA). Potassium hydroxide, 70% perchloric acid,
and L-glutamine were purchased at Merck (Darmstadt, Germany)
and D-glucose at VWR International (Poole, England). Fetal bovine
serum, 10% (FBS) was obtained from Bodinco (Alkmaar, The Neth-
erlands) and bovine serum albumin (BSA) from Sigma (St. Louis,
MO, USA). 15N2-(guanidino)-arginine:HCl (98% 15N2), 13C2–15
N-glycine (98% 13C2, 96–99% 15N), and 13C6–L-lysine:2 HCl (98%
13C6) were obtained from Eurisotop (Saint Aubin Cedex, France).
2.2. Patient samples
The previously described AGAT-deﬁcient lymphoblasts with a
homozygous pathogenic mutation in the AGAT-gene [24] were
used. A control lymphoblastoid cell line was obtained from Centre
d0 Etude du Polymorphisme Humain (Paris, France).
Plasma from a 4-day old male suffering from citrullinemia with
a pathogenic mutation in the arginino succinate synthase (ASS)-
gene, was available for the determination of amino acid levels,
including homoarginine.2.3. Lymphoblasts
Lymphoblasts were cultured in 50 ml RPMI-medium containing
10% FBS and 1% L-glutamine, until conﬂuence was reached. After
harvesting the cells by centrifuging 5 min at 571g and 20 C, the
pellets were washed twice in 25 ml EBSS + 0.1% D-glucose. Next,
intracellular amino acids were depleted essentially as previously
described [25]. In brief, the washed cell pellets were incubated for
1 h at 37 C in 35 ml EBSS supplemented with 0.1% (D-glucose
and 0.25% BSA. After depletion, cells were harvested (5 min,
571g, 20 C), washed twice in 25 ml HBSS, and stored at 20 C.
2.4. Enzyme assays in lymphoblasts
Upon analysis, lymphoblast pellets were thawed on ice. Each
pellet was reconstituted in 1 ml 100 mmol/l Na2HPO4, pH = 7.5
and cells were lysed using an ultrasonic probe (Bandalin Sonopuls
mini 20 with MS 1.5 titanium microtip) for 3  10 s at 0.250 kJ
(=90% of maximum power). After centrifugation (5 min, 8800g,
4 C), 50 ll supernatant was used for the determination of protein
content.
To determine whether AGAT is capable to synthesize homoargi-
nine from arginine and lysine, a lymphoblast lysate sample contain-
ing 50 lg protein was incubated with 30 ll 100 mmol/l
15N2-(guanidino)-arginine and 30 ll 160 mmol/l 13C6-lysine. To
reach a total volume of 200 ll, 100 mmol/l Na2HPO4, pH = 7.5 was
added. At t = 0 and after 18 hours incubation at 37 C, proteins were
precipitated with 30 ll 4 mol/l perchloric acid, and the samples
were neutralized with 20 ll 6 mol/l KOH. After centrifugation, the
supernatant was used to measure the formation of 13C6–15N2-
homoarginine (mass transition 253–89) with an LC-MS/MSmethod
[1]. In short, the internal standard D4-homoarginine was added to
the samples and the basic amino acids were extracted using solid
phase extraction. After derivatization, the resulting butyl ester
derivatives were measured with LC–MS/MS.
To conﬁrm that AGAT is functioning properly, a second assay
was done in which a lymphoblast lysate sample containing 50 lg
protein was incubated with 30 ll 100 mmol/l 15N2-(guanidino)-
arginine and 30 ll 160 mmol/l 13C2–15N-glycine in a total volume
of 200 ll. The formation of 13C2–15N3-guanidino acetate was
measured after 18 h incubation at 37 C using GC–MS [26,27].
Additionally, lactate dehydrogenase (LDH; EC 1.1.1.27.) activity
was determined to conﬁrm viability of both the AGAT-deﬁcient
and the control cell line. Activity was determined using a spectro-
photometric assay, which follows the accumulation of NADH in the
presence of pyruvate [28].
2.5. Measurement of homoarginine in plasma
In a 4-day old ASS-deﬁcient male patient, plasma homoarginine
was determined simultaneously with arginine, monomethylargi-
nine (MMA) and both asymmetric and symmetric dimethylargi-
nine (ADMA and SDMA, respectively) using our recently
validated HPLC method with tandem mass spectrometry detection
[1]. The concentrations of these amino acids were compared to
concentrations measured in plasma of 10 age-matched children
without inborn or acquired disorders of amino acid metabolism.3. Results
3.1. Homoarginine formation in lymphoblasts
Both the lysates of AGAT-deﬁcient and the control cell lines
showed normal LDH-activity, indicating proper quality of the ly-
sates. During the 18-h incubation at 37 C in the presence of
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Fig. 2. Homoarginine formation in AGAT-deﬁcient and control lymphoblasts.
Chromatograms of 15N2–13C6-homoarginine in lymphoblasts of an AGAT-deﬁcient
(AGAT/) patient (upper panel) and a control (AGAT+/+) cell line (lower panel). The
closed line represents the amount of 15N2–13C6-homoarginine present after an 18-
hour incubation at 37 C in the presence of 15N2-(guanidino)-arginine and 13C6-
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produced 0.475 pmol 15N2–13C6-homoarginine/min/mg protein
(Fig. 2). Lysates from the AGAT-deﬁcient lymphoblasts, however,
did not show any detectable 15N2–13C6-homoarginine formation.
To conﬁrm that the control lymphoblasts expressed functional
AGAT, the production of 15N3–13C2-GAA from 15N2-(guanidino)-
arginine and 15N–13C2-glycine was also measured. The lysates of
the control lymphoblasts showed an activity of 27.6 pmol
15N3–13C2-GAA/min/mg protein, which is in line with the previ-
ously reported reference range of 21–70 pmol 15N3–13C2-GAA/
min/mg protein [27]. In the AGAT-deﬁcient lymphoblasts
15N3–13C2-GAA formation was not detectable, conﬁrming the ab-
sence of any residual AGAT-activity. Possible homoarginine forma-
tion from lysine catalyzed by the urea-cycle enzymes would lead to
the formation of 13C6-homoarginine instead of 15N2–13C6-homoar-
ginine, since 15N2-(guanidino)-arginine is not involved. In lysates
of both the AGAT-deﬁcient as well as the control lymphoblasts
formation of 13C6-homoarginine was not detectable.
3.2. Homoarginine in plasma of an ASS-deﬁcient patient
As expected, the plasma arginine concentration in the ASS-deﬁ-
cient patient was very low, that is, 10.8 lmol/l, approximately six-
fold lower than the mean concentration (62.0 ± 20.0 lmol/l) in the
healthy age-matched control subjects. In contrast, the homoargi-
nine concentration in the plasma of the ASS-deﬁcient patient was
approximately eightfold higher than in the age-matched controls
(5.1 lmol/l versus 0.61 ± 0.40 lmol/l, respectively). Concentrations
of the methylated arginines in the plasma of the ASS-deﬁcient pa-
tient were similar to the concentrations measured in the control
subjects (0.65 lmol/l versus 0.81 ± 0.16 lmol/l for ADMA,
0.85 lmol/l versus 0.78 ± 0.36 lmol/l for SDMA, and 0.078 lmol/l
versus 0.109 ± 0.025 lmol/l for MMA).lysine, and the dotted line represents the baseline measurement.4. Discussion
The main ﬁnding of this study is that de novo synthesis of homo-
arginine was not detectable in AGAT-deﬁcient lymphoblasts,
whereas in a control lymphoblast cell line detectable amounts of
homoarginine were newly synthesized from arginine and lysine. A
second key ﬁnding is that in plasma from an ASS-deﬁcient patient
the concentration of homoarginine was eightfold fold higher than
in control subjects, as opposed to the decreased level that would be
expected if the urea-cycle enzymes were mainly responsible for
homoarginine synthesis. In creatine synthesis, the intermediate
GAA is formed by AGAT-catalyzed transfer of an amidino-group be-
tween arginine and glycine. Substrate promiscuity of AGAT leads to
transfer of the amidino-group from arginine to lysine, leading to con-
version of the latter into homoarginine. Overall, our data show that
this promiscuous activity of AGAT, rather than urea cycle enzymes,
is likely responsible fordenovo synthesis of homoarginine inhumans.
Already in 1964 Ryan andWells showed that labeled homoargi-
nine was synthesized from labeled lysine in rats [16], and that in
humans oral administration of lysine resulted in the urinary excre-
tion of homoarginine and homocitrulline. Although this proved
that homoarginine originates from lysine, the possible routes in-
volved remained unclear. After it was shown that arginase is able
to accept homoarginine as a substrate [29], the idea of an alternate
urea-cycle was put forth [23]. Also the involvement of a transam-
idination reaction similar to that of AGAT was suggested by Ryan
et al. [21]. In support of this notion, homoarginine producing plants
contain a gene for an arginine:lysine amidinotransferase [20].
Amidinotranferases are well conserved within plants, but similar-
ity decreases when compared to mammals. The speciﬁc amino acid
binding domains, however, remain conserved [20].Compared to the formation of GAA by AGAT in control lympho-
blasts, the rate of homoarginine synthesis was about 60-fold lower
at similar substrate concentrations. This is in line with homoargi-
nine synthesis by transfer of an amidino-group from arginine to ly-
sine being a secondary activity of AGAT, next to its main role in the
synthesis of GAA from arginine and glycine. It should be noted that
enzyme promiscuity is widespread, probably because the catalysis
of multiple reactions offers evolutionary advantages [30]. There are
several parallels between homoarginine and GAA in support of a
common origin of both metabolites. First, mean levels of both
homoarginine and GAA are higher in men compared to women
[13,31]. Second, both compounds are mainly formed in the kidney
where AGAT is located [16,18], and are signiﬁcantly decreased in
plasma of patients with end-stage renal disease [32].
The elevated homoarginine levels we measured in the ASS-
deﬁcient patient, were also reported in several other urea-cycle
disorders [17,33]. Kato suggested that this elevation is the result
of decreased degradation of lysine, increasing its availability as
substrate for AGAT-catalyzed homoarginine synthesis [34]. An-
other possibility is downregulation of arginase as a compensatory
reaction to the very low levels of arginine associated with ASS-deﬁ-
ciency. Assuming unaltered AGAT-catalyzed synthesis of homoar-
ginine, a reduction of homoarginine degradation by arginase may
then lead to elevated plasma levels.
It should be noted that although our data unequivocally impli-
cate AGAT in homoarginine synthesis, a role of urea-cycle enzymes
cannot be fully excluded. To be able to give a more deﬁnitive an-
swer on the involvement of the urea-cycle enzymes in homoargi-
nine synthesis, measurement of homoarginine synthesis in cell
lines lacking one or more urea-cycle enzymes may be useful.
3656 M. Davids et al. / FEBS Letters 586 (2012) 3653–3657Additionally, it cannot be fully excluded that uptake from the diet
contributes to normal endogenous homoarginine levels, since the
grass pea, lentil and similar legumes, which are used for human
consumption, contain a high amount of non-protein amino acids,
including homoarginine [35–37]. More research is needed to eval-
uate to what extent dietary homoarginine contributes to plasma
levels of homoarginine in humans.
As to whether high or low homoarginine levels are more bene-
ﬁcial with respect to cardiovascular disease, remains to be estab-
lished. Low homoarginine levels have been associated with
cardiovascular risk and mortality [12–14], possibly reﬂecting the
local failing creatine metabolism in the myocardium [19], whereas
high homoarginine levels may interfere with nitric oxide produc-
tion, potentially leading to elevated blood pressure [9]. Research
in the ﬁeld of creatine metabolism has produced an extensive body
of knowledge on the regulation of AGAT activity [18], which may
also provide valuable clues to potential pharmaceutical or dietary
strategies to alter homoarginine synthesis by targeting AGAT. Sup-
plementation with creatine, for example, effectively reduces syn-
thesis of GAA by feedback repression of AGAT and may therefore
also reduce synthesis of homoarginine. In contrast to this expecta-
tion, in healthy volunteers receiving creatine supplementation that
effectively reduced GAA levels, circulating homoarginine levels
were increased by 35% [38]. This likely reﬂects involvement of sec-
ondary pathways, and shows that more research into this ﬁeld is
required.
In conclusion, our data show that promiscuous activity of AGAT,
a key enzyme in the synthesis of creatine, plays a pivotal role in the
synthesis of the novel cardiovascular risk factor homoarginine.
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